Expert Opinion on Drug Safety 2008-09-01

The safety of rosiglitazone in the treatment of type 2 diabetes.

Sonal Singh, Yoon K Loke

Index: Expert Opin. Drug Saf. 7(5) , 579-85, (2008)

Full Text: HTML

Abstract

Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease.To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone.Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers.Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

Related Compounds

  • Rosiglitazone

Related Articles:

Establishment of lipofection for studying miRNA function in human adipocytes.

2014-01-01

[PLoS ONE 9(5) , e98023, (2014)]

ADP-ribosylation factor 6 regulates endothelin-1-induced lipolysis in adipocytes.

2014-08-15

[Biochem. Pharmacol. 90(4) , 406-13, (2014)]

Preconditioning L6 Muscle Cells with Naringin Ameliorates Oxidative Stress and Increases Glucose Uptake.

2015-01-01

[PLoS ONE 10 , e0132429, (2015)]

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

2015-02-01

[Neurobiol. Dis. 74 , 295-304, (2015)]

Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats.

2014-07-01

[J. Diabetes. Investig. 5(4) , 362-71, (2014)]

More Articles...